{"gene":"KLK2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2010,"finding":"KLK2 is the protease responsible for activating PSA (KLK3) zymogen, demonstrated in cell-based in vitro coincubation, xenograft co-inoculation, and prostate-targeted PSA/KLK2 double transgenic mouse models.","method":"Cell-based coincubation assays, xenograft co-inoculation in vivo, and double transgenic mouse models measuring free-to-total PSA ratio","journal":"The Prostate","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal in vitro and in vivo models, including transgenic animals; replicated across experimental systems","pmids":["20058238"],"is_preprint":false},{"year":2010,"finding":"KLK2 degrades IGFBP-3 in vitro via its trypsin-like proteolytic activity, cleaving predominantly after Arg residues to generate multiple small fragments; this fragmentation can be inhibited in a dose-dependent manner by KLK2-inhibiting peptides.","method":"In vitro protease assay with immunoblotting, two specific immunoassays (one recognizing only intact IGFBP-3, one recognizing both intact and cleaved), and mass spectrometry identification of cleavage sites; peptide inhibition assay","journal":"Biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with active-site characterization, cleavage site mapping by MS, and inhibition validation","pmids":["20180640"],"is_preprint":false},{"year":2008,"finding":"KLK2 enzymatic activity can be specifically inhibited by developed peptides; these peptides were shown to bind KLK2 and inhibit its proteolytic activity, and cyclization of the peptides improved their stability.","method":"Peptide-based enzymatic activity assays; cyclization chemistry and stability assessment","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vitro assay with specific inhibitors and structural modification, single lab","pmids":["18627344"],"is_preprint":false},{"year":2014,"finding":"KLK2 cooperates with the androgen receptor (AR) coregulator ARA70 to enhance AR transactivation, promoting prostate cancer cell growth; knockdown of KLK2 with siRNA causes G1 cell cycle arrest and increased apoptosis.","method":"KLK2 cDNA overexpression and siRNA knockdown in LNCaP cells; colony formation assay; in vivo xenograft; AR transactivation reporter assay","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple cellular assays and in vivo xenograft, but mechanistic link to ARA70 is based on functional co-expression without direct binding shown","pmids":["24122203"],"is_preprint":false},{"year":2024,"finding":"KLK2 cleaves the extracellular domain of IL-10 receptor chain 2 (IL-10R2) at the SYRIF sequence (residues 58-63), reducing IL-10R2 surface expression on macrophages and impairing IL-10-mediated suppression of inflammatory responses (decreased nitric oxide, TNF-α, and IL-12p40); KLK2 activity is strongly activated by sodium citrate and glycosaminoglycans at pH 8.0-8.2.","method":"FRET peptide library screening, flow cytometry (FACS) on bone-marrow-derived macrophages, cytokine/NO assays; comparison with KLK3 as negative control","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro substrate identification with FRET library, cell-surface degradation by FACS, and functional cytokine assays; single lab but multiple orthogonal methods","pmids":["39106042"],"is_preprint":false},{"year":2019,"finding":"A KLK2-FGFR2 fusion protein, identified in metastatic prostate cancer, activates downstream FGFR signaling and promotes cell migration when expressed in NIH3T3 cells; it is sensitive to selective FGFR inhibitors.","method":"Targeted RNA sequencing identification; lentiviral transduction of NIH3T3 cells; migration assays; Western blot for FGFR pathway activation; drug sensitivity assays","journal":"Prostate cancer and prostatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 — functional characterization of fusion in cellular model with multiple assays, single lab","pmids":["31043681"],"is_preprint":false},{"year":2002,"finding":"Alternative splicing of KLK2 involving inclusion of intronic sequences adjacent to exon 1 produces a novel protein (hK2-linked molecule, K-LM) that shares only the signal peptide with KLK2; K-LM has no similarity to the kallikrein family.","method":"Molecular cloning, RT-PCR, sequence analysis, and androgen regulation studies","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — mRNA splice variant identification by molecular cloning; functional characterization limited to expression analysis","pmids":["11834722"],"is_preprint":false},{"year":2025,"finding":"KLK2, previously considered solely a secreted serine protease, is expressed on the cell surface of prostate cancer cells, making it targetable by antibody-based therapeutic strategies.","method":"Cell surface localization demonstrated (methods referenced as per related article by Shen et al.)","journal":"Clinical cancer research","confidence":"Low","confidence_rationale":"Tier 3 — localization claim cited from a related article without detailed methods in this abstract","pmids":["40924642"],"is_preprint":false}],"current_model":"KLK2 is a trypsin-like serine protease expressed in prostate luminal epithelium that activates PSA (KLK3) zymogen, degrades IGFBP-3 and IL-10R2 extracellularly (modulating IGF signaling and prostate inflammation), cooperates with ARA70 to enhance androgen receptor transactivation, and is expressed both as a secreted and cell-surface protein; a KLK2-FGFR2 gene fusion can constitutively activate FGFR signaling in metastatic prostate cancer."},"narrative":{"teleology":[{"year":2002,"claim":"Discovery of an alternative splice variant (K-LM) sharing only the signal peptide with KLK2 revealed unexpected transcript complexity at the KLK2 locus, raising the question of whether KLK2 gene products extend beyond the canonical serine protease.","evidence":"Molecular cloning and RT-PCR of KLK2 transcripts in prostate cells","pmids":["11834722"],"confidence":"Medium","gaps":["No protein-level detection of K-LM or functional characterization reported","Physiological relevance of the splice variant remains undefined"]},{"year":2008,"claim":"Development of specific peptide inhibitors of KLK2 confirmed that its trypsin-like catalytic activity could be selectively blocked, providing tools for downstream functional studies.","evidence":"Peptide-based enzymatic activity assays with cyclization chemistry for stability","pmids":["18627344"],"confidence":"Medium","gaps":["Inhibitors tested only in vitro; no cellular or in vivo validation reported","Selectivity across the full kallikrein family not exhaustively profiled"]},{"year":2010,"claim":"The long-standing question of which protease activates PSA zymogen in vivo was resolved by showing KLK2 is responsible, using multiple orthogonal systems including transgenic mice.","evidence":"Cell-based coincubation, xenograft co-inoculation, and prostate-targeted PSA/KLK2 double transgenic mouse models measuring free-to-total PSA ratio","pmids":["20058238"],"confidence":"High","gaps":["Structural basis of KLK2–pro-PSA interaction not determined","Whether other proteases contribute redundantly to PSA activation in human prostate tissue in vivo"]},{"year":2010,"claim":"Identification of IGFBP-3 as a KLK2 substrate expanded KLK2's role beyond PSA activation to extracellular matrix and growth factor signaling regulation.","evidence":"In vitro protease assay with immunoblotting, dual immunoassays, and mass spectrometry cleavage site mapping","pmids":["20180640"],"confidence":"High","gaps":["IGFBP-3 cleavage by KLK2 not demonstrated in prostatic tissue or fluid","Downstream effects on IGF-I bioavailability not measured"]},{"year":2014,"claim":"A nuclear/transcriptional role for KLK2 was suggested by its cooperation with ARA70 to enhance AR transactivation and its requirement for prostate cancer cell proliferation and survival.","evidence":"KLK2 overexpression and siRNA knockdown in LNCaP cells; AR reporter assays; xenograft growth","pmids":["24122203"],"confidence":"Medium","gaps":["No direct physical interaction between KLK2 and ARA70 or AR demonstrated","Whether the protease activity of KLK2 is required for AR coactivation is unknown","Mechanism of G1 arrest upon KLK2 knockdown not delineated"]},{"year":2019,"claim":"Discovery of a KLK2–FGFR2 gene fusion in metastatic prostate cancer showed that KLK2 regulatory elements can drive constitutive FGFR signaling, identifying a potential therapeutic vulnerability.","evidence":"Targeted RNA-seq identification; lentiviral expression in NIH3T3 cells; migration and drug sensitivity assays","pmids":["31043681"],"confidence":"Medium","gaps":["Frequency of KLK2–FGFR2 fusions across prostate cancer cohorts not established","In vivo oncogenic potential of the fusion not tested in prostate models"]},{"year":2024,"claim":"KLK2 was shown to cleave the IL-10R2 extracellular domain on macrophages, establishing a direct mechanism by which prostatic KLK2 promotes inflammation by disabling IL-10 signaling.","evidence":"FRET peptide library screening, FACS on bone-marrow-derived macrophages, cytokine and NO assays","pmids":["39106042"],"confidence":"Medium","gaps":["Cleavage of IL-10R2 not demonstrated in human prostatic tissue or fluid","Whether KLK2-mediated IL-10R2 shedding contributes to prostate cancer immune evasion in vivo is unknown"]},{"year":null,"claim":"The structural determinants of KLK2 substrate specificity across its diverse substrates (pro-PSA, IGFBP-3, IL-10R2) remain undefined, and whether KLK2's intracellular/nuclear functions require its catalytic activity is unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of KLK2 in complex with any substrate or inhibitor","Catalytic vs. non-catalytic contributions to AR coactivation not separated","In vivo relevance of cell-surface KLK2 expression not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,2,4]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,4]}],"pathway":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,4]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4]}],"complexes":[],"partners":["KLK3","IGFBP3","IL10RB","ARA70","FGFR2"],"other_free_text":[]},"mechanistic_narrative":"KLK2 is a trypsin-like serine protease predominantly expressed in prostate luminal epithelium that functions as a key extracellular regulator of the prostatic microenvironment. KLK2 activates the PSA (KLK3) zymogen, as demonstrated across cell-based, xenograft, and transgenic mouse systems, establishing it as the physiological activator of PSA [PMID:20058238]. KLK2 also degrades IGFBP-3 by cleaving after Arg residues, thereby modulating IGF bioavailability [PMID:20180640], and cleaves the extracellular domain of IL-10R2 on macrophages, impairing IL-10-mediated anti-inflammatory signaling and promoting prostatic inflammation [PMID:39106042]. In prostate cancer cells, KLK2 cooperates with the AR coregulator ARA70 to enhance androgen receptor transactivation and promote cell growth, and a KLK2–FGFR2 gene fusion identified in metastatic prostate cancer constitutively activates FGFR signaling and is sensitive to FGFR inhibitors [PMID:24122203, PMID:31043681]."},"prefetch_data":{"uniprot":{"accession":"P20151","full_name":"Kallikrein-2","aliases":["Glandular kallikrein-1","hGK-1","Tissue kallikrein-2"],"length_aa":261,"mass_kda":28.7,"function":"Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P20151/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KLK2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KLK2","total_profiled":1310},"omim":[{"mim_id":"611959","title":"PROSTATE CANCER, HEREDITARY, 15; HPC15","url":"https://www.omim.org/entry/611959"},{"mim_id":"605097","title":"SOLUTE CARRIER FAMILY 45, MEMBER 3; SLC45A3","url":"https://www.omim.org/entry/605097"},{"mim_id":"605096","title":"ANOCTAMIN 7; ANO7","url":"https://www.omim.org/entry/605096"},{"mim_id":"605094","title":"STEAP2 METALLOREDUCTASE; STEAP2","url":"https://www.omim.org/entry/605094"},{"mim_id":"604146","title":"SYNAPTOTAGMIN 7; SYT7","url":"https://www.omim.org/entry/604146"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"prostate","ntpm":530.8}],"url":"https://www.proteinatlas.org/search/KLK2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P20151","domains":[{"cath_id":"2.40.10.10","chopping":"30-258","consensus_level":"medium","plddt":97.4208,"start":30,"end":258}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P20151","model_url":"https://alphafold.ebi.ac.uk/files/AF-P20151-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P20151-F1-predicted_aligned_error_v6.png","plddt_mean":92.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KLK2","jax_strain_url":"https://www.jax.org/strain/search?query=KLK2"},"sequence":{"accession":"P20151","fasta_url":"https://rest.uniprot.org/uniprotkb/P20151.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P20151/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P20151"}},"corpus_meta":[{"pmid":"11834722","id":"PMC_11834722","title":"Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11834722","citation_count":50,"is_preprint":false},{"pmid":"24122203","id":"PMC_24122203","title":"Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24122203","citation_count":48,"is_preprint":false},{"pmid":"20058238","id":"PMC_20058238","title":"Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.","date":"2010","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/20058238","citation_count":33,"is_preprint":false},{"pmid":"25153390","id":"PMC_25153390","title":"Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients.","date":"2014","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25153390","citation_count":31,"is_preprint":false},{"pmid":"17085659","id":"PMC_17085659","title":"Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17085659","citation_count":30,"is_preprint":false},{"pmid":"19823874","id":"PMC_19823874","title":"A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19823874","citation_count":25,"is_preprint":false},{"pmid":"18627344","id":"PMC_18627344","title":"Development of peptides specifically modulating the activity of KLK2 and KLK3.","date":"2008","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18627344","citation_count":24,"is_preprint":false},{"pmid":"24270797","id":"PMC_24270797","title":"Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.","date":"2013","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24270797","citation_count":21,"is_preprint":false},{"pmid":"29614347","id":"PMC_29614347","title":"Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology.","date":"2018","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29614347","citation_count":15,"is_preprint":false},{"pmid":"23204305","id":"PMC_23204305","title":"Birth-and-death of KLK3 and KLK2 in primates: evolution driven by reproductive biology.","date":"2012","source":"Genome biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/23204305","citation_count":13,"is_preprint":false},{"pmid":"20180640","id":"PMC_20180640","title":"Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides.","date":"2010","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20180640","citation_count":11,"is_preprint":false},{"pmid":"38396898","id":"PMC_38396898","title":"Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38396898","citation_count":10,"is_preprint":false},{"pmid":"23359319","id":"PMC_23359319","title":"Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.","date":"2013","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23359319","citation_count":10,"is_preprint":false},{"pmid":"31043681","id":"PMC_31043681","title":"Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.","date":"2019","source":"Prostate cancer and prostatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31043681","citation_count":7,"is_preprint":false},{"pmid":"28216900","id":"PMC_28216900","title":"Trichosanthes kirilowii Exerts Androgenic Activity via Regulation of PSA and KLK2 in 22Rv1 Prostate Cancer Cells.","date":"2017","source":"Pharmacognosy magazine","url":"https://pubmed.ncbi.nlm.nih.gov/28216900","citation_count":3,"is_preprint":false},{"pmid":"23824286","id":"PMC_23824286","title":"Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23824286","citation_count":2,"is_preprint":false},{"pmid":"39106042","id":"PMC_39106042","title":"Extracellular Domain of IL-10 Receptor Chain-2 (IL-10R2) and Its Arginine-Containing Peptides Are Susceptible Substrates for Human Prostate Kallikrein-2 (KLK2).","date":"2024","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39106042","citation_count":1,"is_preprint":false},{"pmid":"37593117","id":"PMC_37593117","title":"KLK2 single-nucleotide polymorphism rs198977 is associated with increased susceptibility and hyperleukocytosis in AML.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37593117","citation_count":1,"is_preprint":false},{"pmid":"40924642","id":"PMC_40924642","title":"Drug Targets in Prostate Cancer: An Appetite for KLK2-Mediated Destruction.","date":"2025","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/40924642","citation_count":1,"is_preprint":false},{"pmid":"41817312","id":"PMC_41817312","title":"Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.","date":"2026","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/41817312","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":11564,"output_tokens":1828,"usd":0.031056},"stage2":{"model":"claude-opus-4-6","input_tokens":5103,"output_tokens":2048,"usd":0.115072},"total_usd":0.146128,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"KLK2 is the protease responsible for activating PSA (KLK3) zymogen, demonstrated in cell-based in vitro coincubation, xenograft co-inoculation, and prostate-targeted PSA/KLK2 double transgenic mouse models.\",\n      \"method\": \"Cell-based coincubation assays, xenograft co-inoculation in vivo, and double transgenic mouse models measuring free-to-total PSA ratio\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal in vitro and in vivo models, including transgenic animals; replicated across experimental systems\",\n      \"pmids\": [\"20058238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"KLK2 degrades IGFBP-3 in vitro via its trypsin-like proteolytic activity, cleaving predominantly after Arg residues to generate multiple small fragments; this fragmentation can be inhibited in a dose-dependent manner by KLK2-inhibiting peptides.\",\n      \"method\": \"In vitro protease assay with immunoblotting, two specific immunoassays (one recognizing only intact IGFBP-3, one recognizing both intact and cleaved), and mass spectrometry identification of cleavage sites; peptide inhibition assay\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with active-site characterization, cleavage site mapping by MS, and inhibition validation\",\n      \"pmids\": [\"20180640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"KLK2 enzymatic activity can be specifically inhibited by developed peptides; these peptides were shown to bind KLK2 and inhibit its proteolytic activity, and cyclization of the peptides improved their stability.\",\n      \"method\": \"Peptide-based enzymatic activity assays; cyclization chemistry and stability assessment\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro assay with specific inhibitors and structural modification, single lab\",\n      \"pmids\": [\"18627344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"KLK2 cooperates with the androgen receptor (AR) coregulator ARA70 to enhance AR transactivation, promoting prostate cancer cell growth; knockdown of KLK2 with siRNA causes G1 cell cycle arrest and increased apoptosis.\",\n      \"method\": \"KLK2 cDNA overexpression and siRNA knockdown in LNCaP cells; colony formation assay; in vivo xenograft; AR transactivation reporter assay\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple cellular assays and in vivo xenograft, but mechanistic link to ARA70 is based on functional co-expression without direct binding shown\",\n      \"pmids\": [\"24122203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KLK2 cleaves the extracellular domain of IL-10 receptor chain 2 (IL-10R2) at the SYRIF sequence (residues 58-63), reducing IL-10R2 surface expression on macrophages and impairing IL-10-mediated suppression of inflammatory responses (decreased nitric oxide, TNF-α, and IL-12p40); KLK2 activity is strongly activated by sodium citrate and glycosaminoglycans at pH 8.0-8.2.\",\n      \"method\": \"FRET peptide library screening, flow cytometry (FACS) on bone-marrow-derived macrophages, cytokine/NO assays; comparison with KLK3 as negative control\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro substrate identification with FRET library, cell-surface degradation by FACS, and functional cytokine assays; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"39106042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A KLK2-FGFR2 fusion protein, identified in metastatic prostate cancer, activates downstream FGFR signaling and promotes cell migration when expressed in NIH3T3 cells; it is sensitive to selective FGFR inhibitors.\",\n      \"method\": \"Targeted RNA sequencing identification; lentiviral transduction of NIH3T3 cells; migration assays; Western blot for FGFR pathway activation; drug sensitivity assays\",\n      \"journal\": \"Prostate cancer and prostatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization of fusion in cellular model with multiple assays, single lab\",\n      \"pmids\": [\"31043681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Alternative splicing of KLK2 involving inclusion of intronic sequences adjacent to exon 1 produces a novel protein (hK2-linked molecule, K-LM) that shares only the signal peptide with KLK2; K-LM has no similarity to the kallikrein family.\",\n      \"method\": \"Molecular cloning, RT-PCR, sequence analysis, and androgen regulation studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mRNA splice variant identification by molecular cloning; functional characterization limited to expression analysis\",\n      \"pmids\": [\"11834722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLK2, previously considered solely a secreted serine protease, is expressed on the cell surface of prostate cancer cells, making it targetable by antibody-based therapeutic strategies.\",\n      \"method\": \"Cell surface localization demonstrated (methods referenced as per related article by Shen et al.)\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — localization claim cited from a related article without detailed methods in this abstract\",\n      \"pmids\": [\"40924642\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KLK2 is a trypsin-like serine protease expressed in prostate luminal epithelium that activates PSA (KLK3) zymogen, degrades IGFBP-3 and IL-10R2 extracellularly (modulating IGF signaling and prostate inflammation), cooperates with ARA70 to enhance androgen receptor transactivation, and is expressed both as a secreted and cell-surface protein; a KLK2-FGFR2 gene fusion can constitutively activate FGFR signaling in metastatic prostate cancer.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"KLK2 is a trypsin-like serine protease predominantly expressed in prostate luminal epithelium that functions as a key extracellular regulator of the prostatic microenvironment. KLK2 activates the PSA (KLK3) zymogen, as demonstrated across cell-based, xenograft, and transgenic mouse systems, establishing it as the physiological activator of PSA [PMID:20058238]. KLK2 also degrades IGFBP-3 by cleaving after Arg residues, thereby modulating IGF bioavailability [PMID:20180640], and cleaves the extracellular domain of IL-10R2 on macrophages, impairing IL-10-mediated anti-inflammatory signaling and promoting prostatic inflammation [PMID:39106042]. In prostate cancer cells, KLK2 cooperates with the AR coregulator ARA70 to enhance androgen receptor transactivation and promote cell growth, and a KLK2–FGFR2 gene fusion identified in metastatic prostate cancer constitutively activates FGFR signaling and is sensitive to FGFR inhibitors [PMID:24122203, PMID:31043681].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery of an alternative splice variant (K-LM) sharing only the signal peptide with KLK2 revealed unexpected transcript complexity at the KLK2 locus, raising the question of whether KLK2 gene products extend beyond the canonical serine protease.\",\n      \"evidence\": \"Molecular cloning and RT-PCR of KLK2 transcripts in prostate cells\",\n      \"pmids\": [\"11834722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No protein-level detection of K-LM or functional characterization reported\",\n        \"Physiological relevance of the splice variant remains undefined\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Development of specific peptide inhibitors of KLK2 confirmed that its trypsin-like catalytic activity could be selectively blocked, providing tools for downstream functional studies.\",\n      \"evidence\": \"Peptide-based enzymatic activity assays with cyclization chemistry for stability\",\n      \"pmids\": [\"18627344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Inhibitors tested only in vitro; no cellular or in vivo validation reported\",\n        \"Selectivity across the full kallikrein family not exhaustively profiled\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The long-standing question of which protease activates PSA zymogen in vivo was resolved by showing KLK2 is responsible, using multiple orthogonal systems including transgenic mice.\",\n      \"evidence\": \"Cell-based coincubation, xenograft co-inoculation, and prostate-targeted PSA/KLK2 double transgenic mouse models measuring free-to-total PSA ratio\",\n      \"pmids\": [\"20058238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of KLK2–pro-PSA interaction not determined\",\n        \"Whether other proteases contribute redundantly to PSA activation in human prostate tissue in vivo\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of IGFBP-3 as a KLK2 substrate expanded KLK2's role beyond PSA activation to extracellular matrix and growth factor signaling regulation.\",\n      \"evidence\": \"In vitro protease assay with immunoblotting, dual immunoassays, and mass spectrometry cleavage site mapping\",\n      \"pmids\": [\"20180640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"IGFBP-3 cleavage by KLK2 not demonstrated in prostatic tissue or fluid\",\n        \"Downstream effects on IGF-I bioavailability not measured\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A nuclear/transcriptional role for KLK2 was suggested by its cooperation with ARA70 to enhance AR transactivation and its requirement for prostate cancer cell proliferation and survival.\",\n      \"evidence\": \"KLK2 overexpression and siRNA knockdown in LNCaP cells; AR reporter assays; xenograft growth\",\n      \"pmids\": [\"24122203\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct physical interaction between KLK2 and ARA70 or AR demonstrated\",\n        \"Whether the protease activity of KLK2 is required for AR coactivation is unknown\",\n        \"Mechanism of G1 arrest upon KLK2 knockdown not delineated\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery of a KLK2–FGFR2 gene fusion in metastatic prostate cancer showed that KLK2 regulatory elements can drive constitutive FGFR signaling, identifying a potential therapeutic vulnerability.\",\n      \"evidence\": \"Targeted RNA-seq identification; lentiviral expression in NIH3T3 cells; migration and drug sensitivity assays\",\n      \"pmids\": [\"31043681\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Frequency of KLK2–FGFR2 fusions across prostate cancer cohorts not established\",\n        \"In vivo oncogenic potential of the fusion not tested in prostate models\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"KLK2 was shown to cleave the IL-10R2 extracellular domain on macrophages, establishing a direct mechanism by which prostatic KLK2 promotes inflammation by disabling IL-10 signaling.\",\n      \"evidence\": \"FRET peptide library screening, FACS on bone-marrow-derived macrophages, cytokine and NO assays\",\n      \"pmids\": [\"39106042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Cleavage of IL-10R2 not demonstrated in human prostatic tissue or fluid\",\n        \"Whether KLK2-mediated IL-10R2 shedding contributes to prostate cancer immune evasion in vivo is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural determinants of KLK2 substrate specificity across its diverse substrates (pro-PSA, IGFBP-3, IL-10R2) remain undefined, and whether KLK2's intracellular/nuclear functions require its catalytic activity is unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No crystal structure of KLK2 in complex with any substrate or inhibitor\",\n        \"Catalytic vs. non-catalytic contributions to AR coactivation not separated\",\n        \"In vivo relevance of cell-surface KLK2 expression not established\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KLK3\",\n      \"IGFBP3\",\n      \"IL10RB\",\n      \"ARA70\",\n      \"FGFR2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}